# A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

> **NCT04440943** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Breast Cancer
- Gastric Cancer
- Renal Cell Carcinoma
- Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Cholangiocarcinoma
- Bladder Urothelial Carcinoma
- MSI-H Colorectal Cancer
- Esophageal Cancer
- Hepatic Cancer
- Head and Neck Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** CDX-527

## Key facts

- **NCT ID:** NCT04440943
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-04-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440943, "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04440943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*